Holen Sie sich die Stockscreener-App
24.61
5.05%
-1.31
Handel nachbörslich:
24.60
-0.010
-0.04%
Schlusskurs vom Vortag:
$25.92
Offen:
$25.84
24-Stunden-Volumen:
2.47M
Relative Volume:
2.02
Marktkapitalisierung:
$1.63B
Einnahmen:
$5.79M
Nettoeinkommen (Verlust:
$-199.61M
KGV:
-8.1761
EPS:
-3.01
Netto-Cashflow:
$-188.48M
1W Leistung:
+0.65%
1M Leistung:
+2.46%
6M Leistung:
+23.36%
1J Leistung:
-40.21%
1-Tages-Spanne:
$24.53
$25.84
1-Wochen-Bereich:
$24.02
$26.33
52-Wochen-Spanne:
$14.40
$47.00
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Firmenname
Celldex Therapeutics Inc
Sektor
Branche
Telefon
908-200-7500
Adresse
53 FRONTAGE ROAD, HAMPTON
Vergleichen Sie CLDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
24.61 | 1.72B | 5.79M | -199.61M | -188.48M | -3.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | Canaccord Genuity | Buy |
| 2025-03-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-02-13 | Eingeleitet | UBS | Buy |
| 2024-10-07 | Eingeleitet | Citigroup | Buy |
| 2024-09-30 | Eingeleitet | Goldman | Neutral |
| 2024-09-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Eingeleitet | Stifel | Buy |
| 2024-06-11 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-20 | Eingeleitet | TD Cowen | Outperform |
| 2023-11-10 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Eingeleitet | Wells Fargo | Underweight |
| 2021-09-17 | Eingeleitet | Jefferies | Buy |
| 2021-09-10 | Eingeleitet | SVB Leerink | Outperform |
| 2021-07-22 | Eingeleitet | Guggenheim | Buy |
| 2020-02-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-11-07 | Eingeleitet | Aegis Capital | Buy |
| 2016-03-08 | Herabstufung | Jefferies | Buy → Hold |
| 2016-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2016-03-07 | Herabstufung | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2016-03-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-08-11 | Bestätigt | Brean Capital | Buy |
| 2015-08-11 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-11 | Bestätigt | ROTH Capital | Buy |
| 2015-06-02 | Bestätigt | WBB Securities | Strong Buy |
| 2014-11-17 | Bestätigt | ROTH Capital | Buy |
| 2014-03-04 | Bestätigt | Oppenheimer | Outperform |
| 2013-07-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-03-08 | Bestätigt | Cantor Fitzgerald | Buy |
| 2013-02-26 | Bestätigt | Oppenheimer | Outperform |
| 2013-01-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2012-10-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-09-14 | Bestätigt | Cantor Fitzgerald | Buy |
Alle ansehen
Celldex Therapeutics Inc Aktie (CLDX) Neueste Nachrichten
Mirador Capital Partners LP Buys 30,843 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
How correlated is Celldex Therapeutics Inc to the S P500Market Growth Report & Entry and Exit Point Strategies - khodrobank.com
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - MSN
Key resistance and support levels for Celldex Therapeutics Inc.2025 AllTime Highs & Consistent Return Investment Signals - newser.com
Shorts Report: Will Celldex Therapeutics Inc benefit from geopolitical trendsTrade Risk Assessment & Weekly Setup with High ROI Potential - khodrobank.com
Sovran Advisors LLC Buys New Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Does Celldex Therapeutics Inc. show high probability of reboundGlobal Markets & Risk Controlled Daily Plans - newser.com
Quarterly Earnings: Can Celldex Therapeutics Inc disrupt its industryJuly 2025 Institutional & Target Return Focused Stock Picks - khodrobank.com
Momentum Shift: Will Celldex Therapeutics Inc benefit from government policyJuly 2025 Setups & Community Verified Swing Trade Signals - khodrobank.com
Should you hold or exit Celldex Therapeutics Inc. nowChart Signals & Weekly Top Stock Performers List - newser.com
Celldex Therapeutics (NASDAQ:CLDX) Given "Buy" Rating at Canaccord Genuity Group - MarketBeat
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in CSU market By Investing.com - Investing.com South Africa
Celldex Therapeutics’ SWOT analysis: barzolvolimab stock potential in CSU market - Investing.com
Celldex reports strong efficacy for urticaria drug regardless of IgE levels - Investing.com Canada
Celldex Therapeutics Says Barzolvolimab Data Shows Sustained Efficacy in Chronic Spontaneous Urticaria - MarketScreener
What are WSFSs technical support levelsQuarterly Portfolio Review & Verified Entry Point Detection - خودرو بانک
Celldex Presents Data Demonstrating Barzolvolimab Improves - GlobeNewswire
71% Complete Response: Celldex's Novel CSU Drug Shows Breakthrough Results for All Patient Types - Stock Titan
Growth Report: Can Celldex Therapeutics Inc disrupt its industryTrade Risk Assessment & AI Forecasted Stock Moves - خودرو بانک
Published on: 2025-09-17 11:44:49 - khodrobank.com
Woodline Partners LP Sells 825,586 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Downgrade Watch: Will Celldex Therapeutics Inc benefit from geopolitical trendsWeekly Trend Report & Smart Swing Trading Techniques - خودرو بانک
Jobs Data: Will Celldex Therapeutics Inc benefit from geopolitical trends2025 Fundamental Recap & Trade Opportunity Analysis - khodrobank.com
Risk Analysis: Can Celldex Therapeutics Inc reach all time highs this yearMarket Performance Report & Accurate Intraday Trading Signals - khodrobank.com
Applying sector rotation models to Celldex Therapeutics Inc.July 2025 PreEarnings & Capital Efficient Trade Techniques - newser.com
Why Celldex Therapeutics Inc. is moving todayJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Market Review: Does Celldex Therapeutics Inc stock benefit from AI growthWeekly Trading Summary & AI Driven Stock Movement Reports - خودرو بانک
Weekly Earnings: Can Celldex Therapeutics Inc navigate macro headwindsWeekly Earnings Recap & AI Powered Buy and Sell Recommendations - khodrobank.com
Will Celldex Therapeutics Inc. rebound enough to break evenProfit Target & Verified Swing Trading Watchlists - newser.com
Pullback Watch: Does Rocket Pharmaceuticals Inc meet Warren Buffetts criteria2025 Major Catalysts & Capital Efficiency Focused Ideas - khodrobank.com
IPO Launch: How correlated is Celldex Therapeutics Inc to the S P5002025 Winners & Losers & Safe Entry Point Identification - khodrobank.com
Travel Stocks: Can Celldex Therapeutics Inc disrupt its industryInsider Buying & Fast Exit Strategy with Risk Control - خودرو بانک
Aug Catalysts: What makes Celldex Therapeutics Inc stock attractive todayJuly 2025 Reactions & High Win Rate Trade Tips - خودرو بانک
Sentiment analysis tools applied to Celldex Therapeutics Inc.Chart Signals & Verified Short-Term Plans - newser.com
Technical signs of recovery in Celldex Therapeutics Inc.Weekly Stock Report & Step-by-Step Swing Trade Plans - newser.com
Is Celldex Therapeutics Inc. reversing from oversold territoryJuly 2025 Retail & Fast Entry High Yield Tips - newser.com
Assessing Celldex Therapeutics's Valuation After Encouraging Phase 2 Barzolvolimab Results and Renewed Pipeline Optimism - Sahm
Celldex Therapeutics, Inc. $CLDX Holdings Decreased by Polar Asset Management Partners Inc. - MarketBeat
Northern Trust Corp Lowers Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Cinctive Capital Management LP Reduces Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
20,899 Shares in Celldex Therapeutics, Inc. $CLDX Bought by PDT Partners LLC - MarketBeat
Trexquant Investment LP Buys Shares of 78,210 Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (CLDX) Reports Promising Phase 2 Study Results For Barzolvolimab - Yahoo Finance
Real time scanner hits for Celldex Therapeutics Inc. explainedJuly 2025 Snapshot & Reliable Entry Point Trade Alerts - Newser
Using flow based indicators on Celldex Therapeutics Inc.July 2025 Momentum & Weekly Breakout Stock Alerts - Newser
Pattern recognition hints at Celldex Therapeutics Inc. upsideLong Setup & Safe Capital Growth Stock Tips - Newser
Should you wait for a breakout in Celldex Therapeutics Inc.2025 Trading Volume Trends & Comprehensive Market Scan Insights - Newser
What technical models suggest about Celldex Therapeutics Inc.’s comebackQuarterly Performance Summary & Fast Moving Market Watchlists - Newser
Custom watchlist performance reports with Celldex Therapeutics Inc.Wall Street Watch & Low Risk High Reward Ideas - Newser
News impact scoring models applied to Celldex Therapeutics Inc.Fed Meeting & Real-Time Buy Signal Alerts - Newser
Building trade automation scripts for Celldex Therapeutics Inc.2025 Pullback Review & Weekly Market Pulse Alerts - Newser
Finanzdaten der Celldex Therapeutics Inc-Aktie (CLDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Celldex Therapeutics Inc-Aktie (CLDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Marucci Anthony S | PRESIDENT & CEO |
Nov 11 '24 |
Buy |
26.82 |
11,500 |
308,430 |
40,284 |
1.43%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):